- Biological therapy by Ocrelizumab (antiCD20) is surprisingly clinically effective in multiple sclerosis patients2017 | Faculty of Medicine in Hradec Králové
- Biologics targeting CD20 molecule on B cells in the therapy of multiple sclerosis patients2022 | Faculty of Medicine in Hradec Králové
- The induction of molecular genetic conversion in bone marrow (BM) in Patients with indolent Lymphomas Treated by Mnoclonal Antibody anti-CD20 (MABTHERA)Publication without faculty affiliation
- B lymphocytes in cerebrospinal multiple sclerosis and the role of a B lymphocyte-targeting biologic agent in its therapy2018 | Faculty of Medicine in Hradec Králové
- Capabilities to modulate inflammation in patients suffering from multiple sclerosis by biologics targeting CD20 molecule on mature B cells are expanding2020 | Faculty of Medicine in Hradec Králové
- Rituximab infusion-related toxicity in patients with chronic lymphocytic leukemia2015 | Faculty of Medicine in Hradec Králové
- MS and NMOSD during the pandemic COVID-19 - what have we already learnt?2021 | First Faculty of Medicine, Faculty of Physical Education and Sport
- Prolymphocytic leukemia2010 | First Faculty of Medicine
- Obinutuzumab in the treatment of non-Hodgkin's B-cell lymphoma - GADOLIN trial2015 | Faculty of Medicine in Hradec Králové
- The terapeutic Options for ""Slow- go"" Patients with Chronic Lymphocytic Leukemia2015 | Faculty of Medicine in Hradec Králové
